We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Personal Cell Analysis System Monitors Treatment of HIV/AIDS

By LabMedica International staff writers
Posted on 27 Oct 2008
A new system, based on the personal cell analysis platform (PCA) platform, is designed for diagnosis and monitoring human immunodeficiency virus infections.

Dubbed the AutoCD4/CD4% system, it includes new automated gating and acquisition software and a single antibody cocktail. More...
Designed specifically to meet the needs and challenges of a broad population of users, the easy-to-use software allows operators with minimal technical expertise to monitor a patient's T-lymphocytes accurately and effortlessly.

From a single assay, a technician can get a patient's CD4 count, total lymphocyte count, and CD4% value with only 10 µl of whole blood, and acquire results with just one click of a button. The CD4% value is particularly critical for pediatric patients.

The new software also includes an error detection feature and easy-to-read results in the form of individual patient as well as summary reports. These features help ensure reproducible, high quality test results from every sample.

Guava Technologies, Inc. (Stamford, UK) launched Guava AutoCD4/CD4% system with the expectation that it will help fight the global AIDS pandemic. "Access to appropriate diagnostic tools is crucial in the battle against HIV/AIDS, and we are committed to developing our clinical cell analysis technology so that it is truly accessible to those who need it anywhere in the world," said Larry Bruder, president & CEO of Guava Technologies. "We designed our AutoCD4/CD4% system so that any healthcare professional-even one without prior experience with flow cytometry-can get accurate and reliable test results every time."

The patented microcapillary design eliminates the need for complicated fluidics making Guava Instruments ideally suited for use anywhere in the world, even in remote regions. They are more compact and have fewer moving parts than most traditional flow cytometers. They also accommodate smaller sample volumes, have lower reagent demands, and generate less waste. Guava Software guides the user through whatever procedure is being conducted, whether it is an assay, instrument setup, or routine maintenance.

Related Links:
Guava Technologies



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Clinical Informatics Platform
CLARION™
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: An elevated neutrophil-to-lymphocyte ratio (NLR), a rato easily obtained from a routine blood count, was associated with both short- and long-term Alzheimer’s risk (photo credit: 123RF)

Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk

Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.